Glioblastoma Multiforme Clinical Trial
Official title:
Pilot Imaging Study to Assess the Distribution of IL13-PE38QQR Cytotoxin Infusions in Patients With Recurrent, Resectable, Supratentorial Malignant Glioma
Verified date | June 2011 |
Source | INSYS Therapeutics Inc |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
The experimental anti-cancer drug IL13-PE38QQR, which is being developed for the treatment
of malignant brain tumors, is composed of parts of two proteins: the immune system cytokine
IL13 and a toxin from the bacterium Pseudomonas aeruginosa. The IL13 part of the drug binds
to another protein, the IL13 receptor, when this receptor is displayed on the outside
surface of cells. Cells with drug bound to the IL13 receptor take up the drug, and the toxin
part of the drug then kills those cells. Since brain tumor cells display the IL13 receptor,
they are potential targets that may be killed by this drug. This is a pilot study to
visualize the distribution of IL13-PE38QQR infused into and around brain tumor tissue before
and after surgical removal of the tumor in adult patients with recurrent malignant glioma.
Stored tumor tissue will be tested for presence of the receptor protein, which is required
for study entry. Eligible patients will then undergo biopsy to confirm the diagnosis of
recurrent malignant glioma. IL13-PE38QQR will be infused for 96 hours into and around tumor
tissue through catheters that have been placed surgically. For the first 48 hours the drug
will be mixed with a radioactive tracer, so that the distribution of the drug can be
followed by a type of scanning called SPECT. Surgery to remove the tumor will be performed
approximately 15 days after the end of the infusion. Catheters will again be placed
surgically, and IL13-PE38QQR will be infused a second time for 96 hours. Radioactive tracer
will be included in the infusion for the first 48 hours. For both infusions, SPECT scans
will be taken at 6, 24, and 48 hours after the start of infusion. MRI scans will be taken
within 90 minutes of the 24 and 48 hour SPECT scans. Patients will be followed closely with
further scans and laboratory tests until completion of the study approximately 58 days after
completion of the second infusion.
Status | Completed |
Enrollment | 18 |
Est. completion date | July 2007 |
Est. primary completion date | June 2006 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
DISEASE CHARACTERISTICS - Archival tumor sample must express IL13Ra2 by immuno-histochemistry (IHC) analysis - Must have prior histologic diagnosis of supratentorial malignant glioma (Grade 3 or 4), including glioblastoma multiforme, anaplastic astrocytoma, anaplastic oligodendroglioma, or mixed oligoastrocytoma (excludes glioma of unknown grade). Patients with clinical/radiographic diagnosis of malignant glioma may be registered pending histologic confirmation. - Must have undergone prior surgical resection and received external beam radiotherapy with at least 48 Gy tumor dose, completed at least 8 weeks prior to study - Must have recurrent or progressive supratentorial malignant glioma compared with a previous diagnostic study - Baseline tumor measured within 2 weeks prior to study entry - Stereotactic biopsy at study entry must confirm the presence of glioma (malignant, unless previously documented) - Recurrent or progressive tumor must have a solid contrast-enhancing region at least 1.0 cm and no more than 5.0 cm in maximum diameter. One satellite lesion is permitted if separated by 3 cm or less from the primary mass. PATIENT CHARACTERISTICS - Age 18 and over - Karnofsky Performance Score of at least 70 - Absolute neutrophil count at least 1500/mm^3 - Hemoglobin at least 10 gm/dL - Platelet count at least 100,000/mm^3 - PT and aPTT within institutional limit of normal - Must be candidate for re-operation - Must have recovered from toxicity of prior therapy. Minimum intervals required: at least 6 months after approved intratumoral chemotherapy (e.g. carmustine wafer), at least 6 weeks after nitrosourea-containing chemotherapy, at least 4 weeks after any investigational agent or any other cytotoxic chemotherapy, at least 2 weeks after vincristine or non-cytotoxic chemotherapy - Must practice an effective method of birth control during the study - Must understand the investigational nature of this study and its potential risks and benefits, and sign an approved written informed consent prior to performance of any study-specific procedure - No patients with tumor crossing the midline (tumor involving corpus callosum is permitted if not crossing midline), more than two foci of tumor, or non-parenchymal tumor dissemination (e.g. subependymal or leptomeningeal) - No patients with impending herniation (e.g. midline shift greater than 1.0 cm), uncontrolled seizures, or requirement for immediate palliative treatment - No patients who have received localized therapy for glioma, e.g. focal single-fraction radiotherapy, brachytherapy, or intracerebral infusion of chemotherapy or cytotoxin - No patients who are receiving any concurrent chemotherapy or any other investigational agent (corticosteroids are permitted) - No patients with a known allergy to iodine or to contrast medium that may be utilized in scans required by this protocol - Female patients must not be pregnant or breast-feeding - No patients unwilling or unable to follow protocol requirements |
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Duke University Medical Center | Durham | North Carolina |
Lead Sponsor | Collaborator |
---|---|
INSYS Therapeutics Inc |
United States,
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05023551 -
Study of DSP-0390 in Patients With Recurrent High-Grade Glioma
|
Early Phase 1 | |
Recruiting |
NCT06059690 -
Biologic Association Between Metabolic Magnetic Resonance-positron Emission Tomograph (MR-PET) and Tissue Measures of Glycolysis in Brain Tumors of Infiltrating Glioblastoma Cells
|
Phase 1/Phase 2 | |
Recruiting |
NCT04116411 -
A Clinical Trial Evaluating the Efficacy of Valganciclovir in Glioblastoma Patients
|
Phase 2 | |
Terminated |
NCT01902771 -
Dendritic Cell Vaccine Therapy With In Situ Maturation in Pediatric Brain Tumors
|
Phase 1 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
Completed |
NCT02386826 -
INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme
|
Phase 1 | |
Completed |
NCT00038493 -
Temozolomide and SCH66336 for Recurrent Glioblastoma Multiforme
|
Phase 2 | |
Withdrawn |
NCT03980249 -
Anti-Cancer Effects of Carvedilol With Standard Treatment in Glioblastoma and Response of Peripheral Glioma Circulating Tumor Cells
|
Early Phase 1 | |
Recruiting |
NCT01923922 -
CT Perfusion in the Prognostication of Cerebral High Grade Glioma
|
N/A | |
Completed |
NCT01956734 -
Virus DNX2401 and Temozolomide in Recurrent Glioblastoma
|
Phase 1 | |
Completed |
NCT01301430 -
Parvovirus H-1 (ParvOryx) in Patients With Progressive Primary or Recurrent Glioblastoma Multiforme.
|
Phase 1/Phase 2 | |
Suspended |
NCT01386710 -
Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Relapsed/Refractory GBM And Anaplastic Astrocytoma
|
Phase 1/Phase 2 | |
Completed |
NCT01402063 -
PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation
|
Phase 2 | |
Active, not recruiting |
NCT00995007 -
A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas
|
Phase 2 | |
Terminated |
NCT00990496 -
A Study Using Allogenic-Cytomegalovirus (CMV) Specific Cells for Glioblastoma Multiforme (GBM)
|
Phase 1 | |
Terminated |
NCT01044966 -
A Study of Intraventricular Liposomal Encapsulated Ara-C (DepoCyt) in Patients With Recurrent Glioblastoma
|
Phase 1/Phase 2 | |
Completed |
NCT00402116 -
Phase 1/2 Study of Enzastaurin in Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma (GS) Patients
|
Phase 1/Phase 2 | |
Completed |
NCT00112502 -
Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme
|
Phase 2 | |
Completed |
NCT00504660 -
6-TG, Capecitabine and Celecoxib Plus TMZ or CCNU for Anaplastic Glioma Patients
|
Phase 2 | |
Recruiting |
NCT05366179 -
Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc
|
Phase 1 |